Genprex, Inc.

NasdaqCM:GNPX Stock Report

Market Cap: US$4.2m

Genprex Management

Management criteria checks 4/4

Genprex's CEO is Ryan Confer, appointed in Sep 2016, has a tenure of 9.25 years. total yearly compensation is $541.57K, comprised of 85.4% salary and 14.6% bonuses, including company stock and options. directly owns 0.029% of the company’s shares, worth $1.18K. The average tenure of the management team and the board of directors is 4.3 years and 5.4 years respectively.

Key information

Ryan Confer

Chief executive officer

US$541.6k

Total compensation

CEO salary percentage85.39%
CEO tenure9.3yrs
CEO ownership0.03%
Management average tenure4.3yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Aug 16
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Jan 31
Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Oct 12
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14
We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27
We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Ryan Confer's remuneration changed compared to Genprex's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$17m

Jun 30 2025n/an/a

-US$18m

Mar 31 2025n/an/a

-US$19m

Dec 31 2024US$542kUS$462k

-US$21m

Sep 30 2024n/an/a

-US$23m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$887kUS$426k

-US$31m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$1mUS$393k

-US$24m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$1mUS$345k

-US$21m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$1mUS$351k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$1mUS$300k

-US$11m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$2mUS$225k

-US$12m

Compensation vs Market: Ryan's total compensation ($USD541.57K) is about average for companies of similar size in the US market ($USD577.34K).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.

CEO

Ryan Confer (43 yo)

9.3yrs
Tenure
US$541,567
Compensation

Mr. Ryan M. Confer, M.S. has been the Chief Financial Officer of Genprex, Inc. since September 2016 and serves as its Chief Executive Officer, President and Director since May 08, 2024. Mr. Confer served a...

Leadership Team

NamePositionTenureCompensationOwnership
Ryan Confer
President9.3yrsUS$541.57k0.029%
$ 1.2k
Mark Berger
Chief Medical Officer4.3yrsUS$551.72k0.016%
$ 644.2
David Schloss
Senior Vice President of Human Resources3.9yrsno datano data
Thomas Gallagher
Senior Vice President of Intellectual Property & Licensing5.3yrsno datano data
Suzanne Thornton-Jones
Senior Vice President of Regulatory Affairs & Quality2.3yrsno datano data
Celina Laney
Chief of Staffno datano datano data
Jack Roth
Chairman of Scientific & Medical Advisory Boardno datano datano data
4.3yrs
Average Tenure

Experienced Management: GNPX's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ryan Confer
President1.6yrsUS$541.57k0.029%
$ 1.2k
Jack Roth
Chairman of Scientific & Medical Advisory Boardno datano datano data
Brent Longnecker
Independent Director5.8yrsUS$75.13k0.0076%
$ 313.4
James E. Rothman
Strategic Advisor to the Board of Directors13.4yrsno datano data
Pasi Antero Janne
Member of Scientific & Medical Advisory Boardno datano datano data
George Peoples
Member of Clinical Advisory Board4.8yrsno datano data
Shu Kam Mok
Member of Scientific & Medical Advisory Boardno datano datano data
George Simon
Member of Scientific & Medical Advisory Boardno datano datano data
William Wilson
Independent Director5.8yrsUS$65.13k0.0068%
$ 281.0
Jose Antonio Toscano
Independent Non-Executive Chairman5.8yrsUS$84.86k0.0068%
$ 281.0
George Gittes
Member of Scientific Advisory Board5.1yrsno datano data
Michael Morse
Member of Clinical Advisory Board4.8yrsno datano data
5.4yrs
Average Tenure
65yo
Average Age

Experienced Board: GNPX's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/28 09:55
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genprex, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners